Guo, R., Yang, G., Feng, Z., Zhu, Y., Yang, P., Song, H., Wang, W., Huang, P., and Zhang, J., Biomater
Peptide therapy results take time
In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), and vomiting (26.1% vs 4.1%)
They are fundamentally different classes of peptides working on different receptor pathways Their combination (CagriSema) delivered 22.7% mean weight loss at 68 weeks vs 16.1% for Semaglutide alone and 11.8% for Cagrilintide alone in the REDEFINE 1 trial In type 2 diabetics, CagriSema achieved 13.7% weight loss vs 3.4% with placebo at 68 weeks The side effects of CagriSema are comparable to semaglutide alone, though GI events and injection site reactions are somewhat higher with the combination What Most People Get Wrong About Cagrilintide vs Semaglutide First, lets clear up the fundamental confusion thats plaguing this entire conversation
This high yield and purity make the GST tag an attractive option for both research and industrial applications
